The FDA rejected Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy for a second time on November 20, 2026, citing data-integrity violations including unauthorized statistical analysis changes and blinding breaches. An FDA advisory panel had voted 9-3 against the drug in July 2026. Capricor shares fell more than 80% in afterhours trading; CEO Linda Marban said deep staff cuts are coming.
FDA rejection of deramiocel
- ▪The FDA rejected Capricor Therapeutics' deramiocel therapy for Duchenne muscular dystrophy on November 20, 2026, determining the evidence did not meet the standard for approval
- ▪Capricor's original deramiocel approval application was denied in July 2025 after the FDA found it lacked substantial evidence of effectiveness
- ▪Capricor resubmitted the deramiocel application after new data from a late-stage study found the drug met its primary and secondary endpoints, showing improved upper limb and cardiac function
- ▪An FDA advisory panel voted 9-3 against deramiocel in July 2026, finding the available evidence did not support the drug's effectiveness
- ▪The November 20, 2026 FDA rejection of deramiocel was the second time the agency had rejected the therapy
Clinical trial data violations
- ▪A group of 28 physicians and researchers involved in deramiocel development sent a letter to senior FDA leadership in October 2026 advocating for the drug's approval
- ▪The plan for how results from deramiocel's late-stage clinical trial would be analyzed changed after the trial had already begun, triggering criticism from FDA staff
- ▪The FDA cited serious data-integrity violations in the deramiocel clinical trial, including unauthorized changes to statistical analyses and breaches of blinding procedures
- ▪The FDA determined the data-integrity problems in a key clinical trial for deramiocel were so severe that the data could not be considered reliable or corrected after the fact
Capricor financial fallout
- ▪Capricor Therapeutics shares fell more than 80% in afterhours trading in New York following the November 20, 2026 FDA rejection of deramiocel
- ▪Capricor Therapeutics CEO Linda Marban said the company would need to make deep cuts to its team following the FDA's rejection of deramiocel
- ▪Capricor Therapeutics shares had dropped more than 73% year to date as of November 20, 2026
- ▪Capricor Therapeutics laid off 10% of its staff in early November 2026 ahead of the FDA's decision on deramiocel
Rare disease treatment debate
- ▪Capricor CEO Linda Marban expressed shock at the FDA's rejection of deramiocel, stating the company did not anticipate the decision
- ▪The FDA's handling of deramiocel was being closely watched by doctors, patients, and industry leaders amid policy changes and a leadership vacuum at the agency
- ▪Capricor CEO Linda Marban said Capricor requested 13 meetings with the FDA from April through October 2026 and the FDA denied each of them
Duchenne muscular dystrophy background
- ▪Deramiocel was designed to protect muscle tissue that Duchenne muscular dystrophy progressively destroys, distinguishing it from other approved drugs that slow the condition or address its genetic mutations
- ▪Approximately 15,000 Americans have Duchenne muscular dystrophy, and the condition affects almost entirely boys
- ▪Duchenne muscular dystrophy is a genetic condition in which the body does not produce the dystrophin protein essential for muscle function
Story comments
Loading comments…